跳至主要内容
临床试验/NL-OMON45180
NL-OMON45180已完成2 期

Regulation of the stress-axis by vitamin D3 in subjects with multiple sclerosis; a double-blinded, randomized, placebo-controlled study - Vitamin D3 and the stress-axis in MS

niversiteit Maastricht0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - relapsing remitting multiple sclerosis (revised McDonald criteria 2005)
  • - age >18 years
  • - premenopausal
  • - At start of study > 6 weeks in clinical remission of disease
  • - use of no immune-modulating treatments or the currently registered firstline immune modulating therapies (including Interferon-beta (1a or 1b), glatiramer acetate, dimethylfumarate, teriflunomide) or second-line immune modulating therapies (incl. fingolimod (Gilenya) and natalizumab (Tysabri)).

排除标准

  • Any contraindication to vitamin D according to Summary of Product Characteristics: Hypercalcaemia, hypervitaminosis D, nephrolithiasis, diseases or conditions resulting in hypercalcaemia and/or hypercalciuria (incl. primary hyperparathyroidism), severe renal impairment.
  • Use of dexamethasone or other systemic glucocorticosteroids <2 months prior to first study visit
  • Supplementation of >=1000 IU/d (25µg) vitamin D2 or D3
  • Medical history of disturbed vitamin D/ calcium metabolism other than low intake
  • Present clinical (major)depression
  • Present treatment with anti-depressants, benzodiazepines, or neuroleptics.
  • Treatment with high-dose dexamethasone for MS exacerbation during study.
  • Pregnancy or the intention to become pregnant during the study period.

研究者

相似试验

Regulation of the stress-axis by vitamin D3 in... | 临床试验